Wonsart CT Tablet is a combination antihypertensive medication containing Telmisartan 40 mg and Chlorthalidone 12.5 mg, indicated for the management of hypertension. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Chlorthalidone, a thiazide-like diuretic, promotes diuresis by inhibiting sodium and chloride reabsorption in the distal convoluted tubules of the kidneys, resulting in reduced plasma volume and peripheral vascular resistance. The combination of these two agents provides complementary mechanisms of action, enhancing antihypertensive efficacy while minimizing adverse effects associated with higher doses of individual agents. Wonsart CT is typically prescribed for patients who require more than one antihypertensive agent to achieve optimal blood pressure control. It is important to monitor renal function, electrolyte levels, and blood pressure regularly during therapy. Contraindications include hypersensitivity to either component, anuria, or severe renal impairment. Use with caution in patients with hepatic impairment or electrolyte imbalances. Wonsart CT Tablet should be taken as directed by a healthcare professional, with adherence to prescribed dosage and lifestyle modifications to optimize therapeutic outcomes.